Evidence map›Paper›PMID 37794134›Full record

ArticleOncogene2023

HMGB1/SET/HAT1 complex-mediated SASH1 repression drives glycolysis and metastasis in lung adenocarcinoma.

Fan Kou, Lei Wu, Yu Zheng, Yeran Yi, Zhenyu Ji, Ziqi Huang, Shiwei Guo, Lili Yang

Abstract read
PubMed Publisher
In one paragraph

Article in Oncogene, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed
1.2field-weighted citation impact, top 20% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed, 8 citations in OpenAlex.

  1. Article
  2. Article
  3. Review
  4. Review
  5. Review
  6. Article
  7. Article
  8. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 1 institution in 1 country.

Fan Kou *Department of Immunology, Tianjin Medical University Cancer Institute & Hospital, Tianjin, China.
Lei Wu *Department of Immunology, Tianjin Medical University Cancer Institute & Hospital, Tianjin, China.
Yu Zheng *Tianjin Medical University Cancer Institute & Hospital, National Clinical Research Center for Cancer, Tianjin, China.
Yeran YiDepartment of Immunology, Tianjin Medical University Cancer Institute & Hospital, Tianjin, China.
Zhenyu JiDepartment of Immunology, Tianjin Medical University Cancer Institute & Hospital, Tianjin, China.
Ziqi HuangDepartment of Immunology, Tianjin Medical University Cancer Institute & Hospital, Tianjin, China.
Shiwei GuoDepartment of Immunology, Tianjin Medical University Cancer Institute & Hospital, Tianjin, China.
Lili YangDepartment of Immunology, Tianjin Medical University Cancer Institute & Hospital, Tianjin, China. yanglili@tjmuch.com.ORCID 0000-0003-4274-4617
Tianjin Medical University Cancer Institute and Hospital · CN

Funding

National Natural Science Foundation of China (National Science Foundation of China) 81974246Natural Science Foundation of Tianjin City (Natural Science Foundation of Tianjin) 22JCYBJC01050
6 · The paper itself

Abstract

High-mobility group box 1 (HMGB1) can enhance the stability and accessibility of nucleus binding sites to nucleosomes and transcription factors. Recently, HMGB1 has been recognized as a positive regulator of tumor glutamine, and its overexpression has been correlated with tumorigenesis and cancer progression. However, functions and mechanisms of HMGB1 in regulation of glycolysis during cancer progression in lung adenocarcinoma (LUAD) is still unclear. Here, we found that intracellular HMGB1 was consistently upregulated in LUAD specimens, and positively relevant to tumor grade and poor survival. HMGB1 facilitated glycolysis and promoted metastasis through physical interaction with SET and HAT1, forming HMGB1/SET/HAT1 complex that inhibited H3K9 and H3K27 acetylation in LUAD. The functional proteins complex coordinated histone modification to suppress the expression of SASH1, thus further facilitating glycolysis and inducing the metastasis in vitro and in vivo. Consistent with this, the expression of SASH1 was negatively correlated with HMGB1, SET and GLUT1, and positively correlated with HAT1 in human LUAD specimens. Clinically, LUAD patients with high expression of HMGB1 and low expression of SASH1 exhibited the worst clinical outcomes. Overall, the findings of this study revealed the critical role of HMGB1 in glycolysis and metastasis by attenuating H3K9ace and H3K27ace through physical interacted with SET and HAT1, which may facilitate future targeted therapies.

Indexed as

Adenocarcinoma of LungHMGB1 ProteinLung NeoplasmsCell Line, TumorCell ProliferationGene Expression Regulation, NeoplasticGlycolysisHistonesHumansTumor Suppressor ProteinsHistonesHMGB1 ProteinSASH1 protein, humanTumor Suppressor Proteins

Identifiers

PMID37794134
OpenAlexW4387330452

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.